Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Polymyalgia rheumatica

Granville Morris
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.10-6-641
Clin Med December 2010
Granville Morris
Consultant geriatrician, Prince Philip Hospital, Llanelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Editor – Dasgupta, writing on behalf of the polymyalgia rheumatica (PMR) guideline development group, presents a welcome and thorough overview of this common condition (Clin Med June 2010 pp 270–4). I have concerns with the recommended three-monthly ‘lab monitoring’ of full blood count, erythrocyte sedimentation rate/C-reactive protein (ESR/CRP), urea and electrolytes and glucose. The management of straightforward PMR is to relieve symptoms (and not to treat inflammation) until the condition runs its natural course. Steroid withdrawal should be based on the clinical picture and not on the level of ESR and this is alluded to in the article ‘raised ESR/CRP without clinical symptoms is not an indication to continue corticosteroids’.

It is my belief, based on reviewing many patients with PMR and iatrogenic Cushing's/osteoporosis, that the main reason for the continuation of higher dose steroids is the regular checking of an ESR to follow disease activity. The secret to the successful management of straightforward PMR is, once the diagnosis has been made, never to check an ESR/CRP unless there is a clinical indication.

Polymyalgia rheumatica

Editor – We thank Dr Morris for highlighting an important issue – the objectives of steroid treatment for polymyalgia rheumatica (PMR). Steroids are prescribed for their important effect on pain, disability and stiffness and the quality of life in untreated PMR is lower than in most other comparable conditions. On the other hand steroids also have many side effects and over-treatment based on raised inflammatory markers alone may prolong duration of treatment and induce treatment co-morbidities such as fractures, diabetes, hypertension, weight gain and cataracts.

However, we now know that the PMR constitutes only one of many conditions that can present with bilateral shoulder pain and stiffness. Such conditions include late onset rheumatoid arthritis, other arthropathies, spondyloarthropathies and connective tissue diseases. Large vessel vasculitis may also present with polymyalgia, constitutional symptoms and raised inflammatory markers. Other serious pathology, such as systemic infection, disseminated cancer and so on, may also be mistaken as PMR and may have an initial response to high dose steroids.

We therefore stand by our recommendation of inflammatory marker testing in the context of a clinical review – especially in the first year of disease. Transient elevations of CRP/ESR may be due to common causes such as urinary or chest infections and urinalysis and chest radiographs may be considered. Persistent elevation in the presence of definite symptoms suggests partial or non-response to steroids, search for alternative pathology or adjuvant immunosuppresives and a specialist referral. Persistent symptoms in the absence of elevated markers suggests evaluation of co-existing non-inflammatory conditions such as osteoarthritis, rotator cuff and other local shoulder conditions, fibromyalgia, etc. These conditions should be dealt with by explanation, reassurance and local treatments such physiotherapy, injections and exercises; while the steroid dose is tapered.

Footnotes

  • Please submit letters for the editor's consideration within three weeks of receipt of the Journal. Letters should ideally be limited to 350 words, and sent by email to: clinicalmedicine{at}rcplondon.ac.uk

  • Royal College of Physicians

Footnotes

  • Please submit letters for the editor's consideration within three weeks of receipt of the Journal. Letters should ideally be limited to 350 words, and sent by email to: clinicalmedicine{at}rcplondon.ac.uk

  • Royal College of Physicians
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Polymyalgia rheumatica
Granville Morris
Clinical Medicine Dec 2010, 10 (6) 641; DOI: 10.7861/clinmedicine.10-6-641

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Polymyalgia rheumatica
Granville Morris
Clinical Medicine Dec 2010, 10 (6) 641; DOI: 10.7861/clinmedicine.10-6-641
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • Footnotes
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 infection despite vaccination: an under-reported COVID-19 cohort
  • Mitral stenosis-related pulmonary embolism as a potential cause of vocal cord paralysis
  • JAK-inhibition as a therapeutic strategy for refractory primary systemic vasculitides
Show more Letters to the editor

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians